New York, NYCIK 18264344 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
15 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 603.1K | $124.82M | 16.2% | +300.3K | Added |
| 2 | Danaher Corporation | 346.9K | $79.41M | 10.3% | +346.9K | New |
| 3 | Eli Lilly & Co | 63.3K | $68.01M | 8.8% | +63.3K | New |
| 4 | United Therapeutics Corp Del |
| 120.9K |
| $58.92M |
| 7.7% |
| −1.3K |
| Reduced |
| 5 | Ascendis Pharma A/S | 265.0K | $56.51M | 7.3% | +90.2K | Added |
| 6 | Madrigal Pharmaceuticals Inc | 86.0K | $50.09M | 6.5% | +18.3K | Added |
| 7 | Boston Scientific Corp | 520.5K | $49.63M | 6.4% | +520.5K | New |
| 8 | Teva Pharmaceutical Inds Ltd | 1.44M | $44.81M | 5.8% | +1.44M | New |
| 9 | Ionis Pharmaceuticals Inc | 557.2K | $44.08M | 5.7% | +557.2K | New |
| 10 | Vera Therapeutics Inc | 805.7K | $40.80M | 5.3% | −384.5K | Reduced |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio